Skip to main content
Clinical Trials/CTRI/2018/05/013927
CTRI/2018/05/013927
Recruiting
Phase 4

A Comparative Clinical Study to Evaluate Efficacy and Safety of Immusante as in the Prevention and Treatment of Chemotherapy Induced Neutropenia

The Himalaya Drug Company0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Cancer subjects with chemotherapy induced neutropenia
Sponsor
The Himalaya Drug Company
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Both male and female patients aged more than 18 years
  • Cancer patients except for blood cancer, receiving chemotherapy and or radiotherapy.
  • Performance status Eastern Cooperative oncology Group (ECOG) \<\= 2
  • Patient with a neutrophil count \> 500 cell/cc
  • Patients who were known to had Neutrophilia in the first cycle of chemotherapy of planned chemotherapy of four cycles.
  • Patients who are planned with at least four more cycles of chemotherapy.
  • Able to comply with the protocol and willing to sign the informed consent form.

Exclusion Criteria

  • Patients with active uncontrolled infection
  • Inadequate renal or hepatic function tests.
  • Any evidence or history of hypersensitivity to herbal medicines.
  • Recurrent/refractory/metastatic carcinomas
  • Severe, life threatening complications associated with carcinoma
  • Severe febrile neutropenia with neutrophil count of 500 cells/cc or below
  • Not recovered from acute toxicities of the prior therapies.
  • Not willing to sign the informed consent or abide by the study procedure.
  • Pregnant or lactating women or women in the reproductive age group not willing to use an effective contraceptive measures.

Outcomes

Primary Outcomes

Not specified

Similar Trials